PABLO DE LA
CUEVA DOBAO
Profesor asociado de Ciencias de la Salud
Ricardo
Ruiz Villaverde
Publications by the researcher in collaboration with Ricardo Ruiz Villaverde (16)
2024
-
Defining well-being in psoriasis: A Delphi consensus among healthcare professionals and patients
Scientific Reports, Vol. 14, Núm. 1
-
Efficacy of Risankizumab in Patients with Suboptimal Response or Failure to Ustekinumab: A Multicenter Retrospective Study in Spain
Dermatologic Therapy, Vol. 2024
-
Family Planning Concerns Among Women With Psoriasis: A Descriptive, Cross-Sectional, Multicenter Study
Actas Dermo-Sifiliograficas, Vol. 115, Núm. 1, pp. 10-20
-
Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice
Experimental Dermatology, Vol. 33, Núm. 8
-
Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice
Journal of the European Academy of Dermatology and Venereology, Vol. 38, Núm. 9, pp. 1783-1790
-
Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study
Actas Dermo-Sifiliograficas
2023
-
Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP)
Actas Dermo-Sifiliograficas
-
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525
-
Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results
Clinical and experimental dermatology, Vol. 48, Núm. 9, pp. 991-997
-
[Translated article] Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis
Actas Dermo-Sifiliograficas, Vol. 114, Núm. 6, pp. T494-T501
2022
2021
-
A new classification of the severity of psoriasis: What’s moderate psoriasis?
Life, Vol. 11, Núm. 7
2020
-
The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: A Spanish multicentre retrospective study
Dermatologic Therapy, Vol. 33, Núm. 6
2018
-
Redefining the therapeutic objective in psoriatic patients candidates for biological therapy
Journal of Dermatological Treatment, Vol. 29, Núm. 4, pp. 334-346
2017
-
Fiabilidad de una aplicación de ayuda a la toma de decisiones terapéuticas en el paciente con psoriasis (MDi Psoriasis®)
Actas Dermo-Sifiliograficas, Vol. 108, Núm. 7, pp. 650-656
-
Reliability of the MDi Psoriasis® Application to Aid Therapeutic Decision-Making in Psoriasis
Actas Dermo-Sifiliograficas, Vol. 108, Núm. 7, pp. 650-656